Two Japan deep-tech startups complete Series B second closes
Helical Fusion and Celaid Therapeutics have raised JPY3.23bn and JPY400m, respectively, as Japanese capital targets research-intensive startups.
October 09, 2026
Unprofitable, fast-growing Chinese startups have, for the last five years, been able to tap private investors flush with cash, allowing them to put off filing for an initial public offering and the associated public scrutiny of their accounts: that will no longer be the easy option.
Registered users get 2 free articles in 30 days.
Subscribers have full unlimited access to FinanceAsia.
Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.
Questions?
See here for more information on licences and prices, or contact [email protected].